What is Joint Academy?
Joint Academy, developed in collaboration with leading osteoarthritis researchers, orthopedic specialists, and experienced physiotherapists, offers a scientifically-backed, long-term treatment for osteoarthritis. Adhering to national and international treatment guidelines and operating under the same regulatory standards as traditional healthcare, the company prioritizes patient data privacy and security. Its treatment, developed by Arthro, has been validated through peer-reviewed studies, demonstrating its efficacy.
How much funding has Joint Academy raised?
Joint Academy has raised a total of $30M across 2 funding rounds:
Series A
$7M
Series B
$23M
Series A (2018): $7M, investors not publicly disclosed
Series B (2020): $23M led by Kinnevik
Key Investors in Joint Academy
Kinnevik
Kinnevik is an industry-focused investment company with an entrepreneurial spirit, dedicated to building digital consumer businesses. They partner with founders to create and lead fast-growing companies, aiming to deliver both shareholder and social value.
What's next for Joint Academy?
The recent major strategic investment positions Joint Academy for significant scaling and market penetration. With a strong scientific foundation and a focus on digital healthcare delivery, the company is poised to expand its reach. Future endeavors will likely involve enhancing its digital platform, broadening its therapeutic offerings, and potentially exploring new markets. The enterprise-level backing suggests a strategic focus on long-term growth and solidifying its position as a leader in digital osteoarthritis management.
See full Joint Academy company page
